Primary Antibodies for Cancer Research

Atlas Antibodies develops and offers a wide selection of PrecisA Monoclonals and Triple A Polyclonals targeting:

Cancer Stem Cell , Mechanisms in Cancer, Glioma, Neuroendocrine NeoplasmsOncology Biomarkers,
Epithelial-to-Mesenchymal Transition, GPCRs,
Colorectal and Breast cancer

Polyclonal antibodies covering the 17 most common cancer types

Atlas Antibodies offers 21,000 Triple A Polyclonals, each supplied with more than 500 annotated IHC images, including images from cancerous tissues.

The antibodies have been used for staining 48 normal human tissue samples and human cancer samples covering the 17 most common cancer types and up to 12 patients for each cancer type.



Explore full catalog

Polyclonal antibodies covering the 17 most common cancer types

Cancer Stem Cell Markers

Cancer stem cells (CSCs) are a small number of cells that drive the tumor’s initiation, growth and metastasis, and may cause relapse.


Due to their importance, several biomarkers that characterize CSCs have been identified, allowing diagnostic, therapeutic, and prognostic predictions.


Atlas Antibodies offers antibodies targeting several proteins relevant as CSC markers, focusing on solid and hematological cancers.


Read White Paper Cancer Stem Cell Markers


Explore Cancer Stem Cell Markers

Cancer Stem Cell Markers

Mechanisms in Cancer

PrecisA Monoclonals and Triple A Polyclonals are in-house developed antibodies for dedicated targets.

Atlas Antibodies selects clones recognizing unique non-overlapping epitopes and/or isotypes.

Our antibodies are covering wide range of cellular processes in cancer:

Read White Paper Mechanisms in Cancer


Explore Mechanisms in Cancer

Mechanisms in Cancer

Neuroendocrine Neoplasms Markers

Neuroendocrine neoplasms (NENs) constitute a group of tumors that derive from the sensory and secretory neuroendocrine cells of the diffuse endocrine system.

There is an unmet need for accurate biomarkers that can be used for NEN diagnosis, prognosis and follow-up, therapy stratification, and evaluation of treatment response.

Discover our newly released PrecisA Monoclonals useful for the immunohistological profiling of NENs.

Read White Paper Neuroendocrine Neoplasms Markers


Explore Neuroendocrine Neoplasms Markers

Neuroendocrine Neoplasms Markers

Glioma Markers

Atlas Antibodies offers antibodies targeting the glioma proteome, the tumor microenvironment and the key molecular markers for glioma classification.

Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. 

Read White Paper Glioma Markers  

Explore Glioma Markers

Markers for Glioma Classification

ATRX has become a routine marker for the classification of gliomas and is most often used in combination with various other markers such as IDH1 and GFAP.

We also suggest related products.

Read White Paper ATRX Glioma Marker

Explore ATRX Marker 

Oncology Biomarkers

Atlas Antibodies recognizes the need for new biomarkers to provide a more accurate diagnosis and a better assessment of patient prognosis, ultimately leading to a more individualized treatment.


Together with our research partners in the Human Protein Atlas project, we are in a unique position to perform antibody-based biomarker discovery.


Learn about Atlas Antibodies oncology biomarkers T-PIT / TBX19, SATB2, PODXL and RBM3.

Read White Paper Oncology Biomarkers


Explore oncology biomarkers

Oncology Biomarkers
Ovarian Cancer Markers

Ovarian Cancer Markers

Atlas Antibodies has released new PrecisA MonoclonalTM antibodies targeting 23 proteins relevant to ovarian cancers (such as high and low-grade serous, endometrioid, clear cell, and mucinous carcinomas), with diagnostic and prognostic values validated on human cancer tissues.

Among the new markers with high potential use as diagnostic tools for ovarian cancers, CD44, NAPSA, and HE4 (WFDC2), have already demonstrated clinical results. 

Read White Paper Ovarian Cancers Markers

Download Infographic

Discover more

Markers in Gynecological Cancers

Markers in Gynecological Cancers

Gynecological cancers affect the reproductive organs of women. The main types of gynecologic cancer are: endometrial, cervical, ovarian, uterine, vaginal/vulvar. A sixth type of gynecologic cancer is the sporadic fallopian tube cancer.

Of all the gynecological cancers, only cervical cancer has screening tests to find this cancer early, when treatment can be most effective.

Therefore, there is a high demand to identify biomarkers specific to these diseases for screening for early detection and new therapeutic targets.

Read White Paper Prognostic Markers in Gynecological Cancers


GPCRs Markers

G protein-coupled receptors (GPCRs) allow the communication between the environment and the cell’s interior: they transduce extracellular stimuli into intracellular signals.


GPCRs play an essential role in different physiological functions and have been well documented in many forms of cancer, contributing to cancer proliferation, angiogenesis, invasion, and metastasis.


Read White Paper GPCRs Markers


Explore GPCRs markers

GPCRs Markers
Colorectal Cancer

Colorectal Cancer

A large number of our antibodies are relevant for scientists studying colorectal cancer. In this brochure, we catalog our antibodies related to the field of colorectal cancer research together with publication references.

Explore our colorectal cancer catalog

Breast Cancer

Breast Cancer

A wide range of our antibodies is used by scientists working to understand breast cancer. In this brochure, we catalog our antibodies related to the field of breast cancer research together with publication references.

Explore our breast cancer catalog

Epithelial-to-Mesenchymal Transition Markers

The Epithelial-to-Mesenchymal Transition (EMT) is a process that normally occurs during embryogenesis, but is also present in wound healing and cancer progression of epithelial tumors.


The EMT marker antibody panel consists of PrecisA Monoclonals manufactured by Atlas Antibodies targeting key EMT markers for cell junctions, cytoskeletal changes, transcription regulation and migration/motility.

Read White Paper EMT Markers

Explore EMT markers

Epithelial-to-Mesenchymal Transition  Markers

The Pathology Atlas

The Pathology Atlas, part of the large Human Protein Atlas project, contains information based on mRNA and protein expression data from 17 different forms of human cancer.

Explore the Pathology Atlas

The Tissue Atlas

The Tissue Atlas, section of the Human Protein Atlas, focus on the expression profiles in human tissues of genes both on the mRNA and protein level.

Explore the Tissue Atlas

Cancer related blog posts

Cancer studies that have used polyclonals from Atlas Antibodies

Research Roundup: cancer research

Read Blog Post

Five questions to better understand T-cell receptors therapy

So what do you know about T-Cell therapy?

Read Blog Post

Ion channels as promising biomarkers in cancer

Voltage-gated ion channels, cancer development, and metastasis.

Read Blog Post

Browse primary antibodies

Find the antibody you need in our product catalog. 

Browse products

Scientific Support

Need help finding the right product or advice on how to use our products?

Find everything you need in our scientific support section. 

Go to Scientific Support

Customer Support

Do you need help on how to buy our products, or information about shipping and payments?

Find the information you need in our customer support section.

Go to Customer Support